Dura mater graft‐associated Creutzfeldt‐Jakob disease with 30‐year incubation period

Over 60% of all patients with dura mater graft‐associated Creutzfeldt‐Jakob disease (dCJD) have been diagnosed in Japan. The incubation period has ranged from 1 to 30 years and the age at onset from 15 to 80 years. Here, we report a 77‐year‐old male Japanese autopsied dCJD case with the longest incubation period so far in Japan. He received a cadaveric dural graft at the right cranial convexity following a craniotomy for meningioma at the age of 46. At 30 years post‐dural graft placement, disorientation was observed as an initial symptom of dCJD. He rapidly began to present with inconsistent speech, cognitive impairment and tremor of the left upper extremity. Occasional myoclonic jerks were predominantly observed on the left side. Brain MRI presented hyperintense signals on diffusion‐weighted and T2‐weighted images, at the right cerebral cortex. The most hyperintense lesion was located at the right parietal lobe, where the dura mater graft had been transplanted. Single‐photon emission CT scan showed markedly decreased cerebral blood flow at the right parietal lobe. EEG revealed diffuse and slow activities with periodic sharp‐wave complex discharges seen in the right parietal, temporal and occipital lobes. He died of pneumonia 9 months after onset. Brain pathology revealed non‐plaque‐type dCJD. Laterality of neuropathological changes, including spongiform change, neuronal loss, gliosis or PrP deposits, was not evident. Western blot analysis showed type 1 PrPCJD. Alzheimer‐type pathology and PSP‐like pathology were also observed.

[1]  A. Aguzzi,et al.  Amyloid-β pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt-Jakob disease after dural grafting. , 2016, Swiss medical weekly.

[2]  Y. Hashizume,et al.  Relation between clinical findings and progression of cerebral cortical pathology in MM1-type sporadic Creutzfeldt–Jakob disease: Proposed staging of cerebral cortical pathology , 2014, Journal of the Neurological Sciences.

[3]  Y. Matsuura,et al.  Distinct origins of dura mater graft-associated Creutzfeldt-Jakob disease: past and future problems , 2014, Acta Neuropathologica Communications.

[4]  N. Saito,et al.  Insight into the frequent occurrence of dura mater graft-associated Creutzfeldt-Jakob disease in Japan , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[5]  D. Bennett,et al.  The Complex PrPc-Fyn Couples Human Oligomeric Aβ with Pathological Tau Changes in Alzheimer's Disease , 2012, The Journal of Neuroscience.

[6]  L. Schonberger,et al.  Iatrogenic Creutzfeldt-Jakob Disease, Final Assessment , 2012, Emerging infectious diseases.

[7]  Y. Kuroiwa,et al.  Prospective 10-year surveillance of human prion diseases in Japan. , 2010, Brain : a journal of neurology.

[8]  H. Mizusawa,et al.  Dura mater graft‐associated Creutzfeldt‐Jakob disease in Japan: Clinicopathological and molecular characterization of the two distinct subtypes , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

[9]  M. Masuda,et al.  [Dura mater related Creutzfeldt-Jakob disease in Japan: relationship between sites of grafts and clinical features]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[10]  R. Barker,et al.  Dura mater-associated Creutzfeldt–Jakob disease: experience from surveillance in the UK , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  S. Ibayashi,et al.  Increased asymmetric pulvinar magnetic resonance imaging signals in Creutzfeldt–Jakob disease with florid plaques following a cadaveric dura mater graft , 2006, Neuropathology : official journal of the Japanese Society of Neuropathology.

[12]  H. Budka,et al.  Alzheimer-type neuropathology in a 28 year old patient with iatrogenic Creutzfeldt-Jakob disease after dural grafting , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  G. V. Van Hoesen,et al.  Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease , 2004, The Journal of Neuroscience.

[14]  Tomoyuki N. Tanaka,et al.  Association of an 11-12 kDa protease-resistant prion protein fragment with subtypes of dura graft-associated Creutzfeldt-Jakob disease and other prion diseases. , 2003, The Journal of general virology.

[15]  Masahito Fushimi,et al.  PLEDs in Creutzfeldt–Jakob disease following a cadaveric dural graft , 2002, Clinical Neurophysiology.

[16]  H. Mizusawa,et al.  Creutzfeldt-Jakob disease after Jannetta’s operation with cadaveric dura mater graft: initial manifestations related to the grafted site , 2002, Journal of Neurology.

[17]  P Brown,et al.  Classification of sporadic Creutzfeldt‐Jakob disease based on molecular and phenotypic analysis of 300 subjects , 1999, Annals of neurology.

[18]  P. Blumbergs,et al.  Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin. , 1990, Australian and New Zealand journal of medicine.

[19]  P. Brown Human growth hormone therapy and Creutzfeldt-Jakob disease: a drama in three acts. , 1988, Pediatrics.

[20]  R. Purcell,et al.  SEROLOGICAL RESPONSE TO THE HEPATITIS DELTA VIRUS IN HEPATITIS D , 1987, The Lancet.

[21]  R. Will,et al.  Evidence for case-to-case transmission of Creutzfeldt-Jakob disease , 1982, Journal of neurology, neurosurgery, and psychiatry.

[22]  D. Gajdusek,et al.  DANGER OF ACCIDENTAL PERSON-TO-PERSON TRANSMISSION OF CREUTZFELDT-JAKOB DISEASE BY SURGERY , 1977, The Lancet.

[23]  N. Da Letter: Hepatitis with hindsight. , 1974 .

[24]  A. Devoe,et al.  Letter: Possible person-to-person transmission of Creutzfeldt-Jakob disease. , 1974, The New England journal of medicine.